Vir and GSK are looking ahead to an imminent readout for their mAb to treat high-risk COVID-19 outpatients after a DSMB recommended the closure of a study arm evaluating the therapy in hospitalized patients. Vir...

Led by Sean Nolan as executive chairman and Joe Nolan as CEO, the former management team of AveXis partnered with Deerfield Management to launch Jaguar Gene Therapy LLC. Jaguar’s preclinical pipeline of AAV9-based gene therapies...

Kite Pharma veteran Ken Takeshita will join Daiichi Sankyo Co. Ltd. (Tokyo:4568) as global head of R&D, succeeding Junichi Koga, who is retiring after more than a dozen years at the Japanese pharma. Kite, a unit of Gilead...

As BMS builds out its early pipeline to find its next big act in cancer and head off revenue losses from upcoming patent cliffs, it’s taking a broad sweep across oncology’s hottest target spaces...

Rigel’s deal with Lilly for its clinical RIPK1 program will triple the biotech’s cash balance as it seeks to expand the label of its sole marketed product while also developing a wholly owned, earlier-stage clinical...

After Qiming closed its sixth RMB fund in late January, Managing Partner Nisa Leung is looking ahead to her firm’s second public listing this year, one that she believes could clear a path for...

With Sana’s underwriters exercising their option to buy more shares in its IPO, the company has closed the offering at $675.6 million, leapfrogging Moderna’s 2018 offering to become the largest yet by a pure-play biotech....

Backed by Hillhouse’s deep pockets, Overland aims to leverage its parent firm’s biopharma ecosystem in China to bring first-in-class and best-in-class Western therapies to the country. Overland Pharmaceuticals launched...

With the acquisition of cannabinoid therapeutics company GW in Jazz’s largest deal ever, the company added a product and pipeline that complements its historical strength in neuroscience rather than oncology, where it has sought to...

While Sana’s massive IPO drew most of the attention among new listings Thursday, biotechs Sensei and Landos made quieter NASDAQ debuts, with several more companies set to price for Friday’s session. Sensei Biotherapeutics Inc. (NASDAQ:SNSE)...